Toll pathway-dependent blockade of CD4(+)CD25(+) T cell-mediated suppression by dendritic cells

Yale University, New Haven, Connecticut, United States
Science (Impact Factor: 31.48). 03/2003; 299(5609):1033-6. DOI: 10.1126/science.1078231
Source: PubMed

ABSTRACT Toll-like receptors (TLRs) control activation of adaptive immune responses by antigen-presenting cells (APCs). However, initiation of adaptive immune responses is also controlled by regulatory T cells (TR cells), which act to prevent activation of autoreactive T cells. Here we describe a second mechanism of immune induction by TLRs, which is independent of effects on costimulation. Microbial induction of the Toll pathway blocked the suppressive effect of CD4+CD25+ TR cells, allowing activation of pathogen-specific adaptive immune responses. This block of suppressor activity was dependent in part on interleukin-6, which was induced by TLRs upon recognition of microbial products.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is well established that CD8 + cytotoxic T lymphocytes (CTLs) play a major role in eradicating tumor cells. The path from naive CD8 + T cell to effector CD8 + T cell is guided by antigen presenting cells, such as dendritic cells (DCs) that start a developmental program in the CD8 + T cells through the delivery of MHC/peptide complexes, co-stimulatory and pro-inflammatory signals. These signals determine the magnitude of the ensuing response and the ability of the CD8 + CTLs to successfully complete their quest, eradicating tumor cells whilst conquering enemies, such as immunosuppressive regulatory T cells (Tregs). In this chapter, we discuss the role of DCs and of the signals critical for effector CD8 + T cell differentiation, and how the differences in the nature of these signals contribute to the diversity of CD8 + T cell responses. No part of this digital document may be reproduced, stored in a retrieval system or transmitted commercially in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services.
    Horizons in Cancer Research, Edited by Hiroto S. Watanabe, 01/2013: chapter Priming of Cytotoxic T Lymphocyte Responses by Dendritic Cells: Induction of Potent Anti-tumor Immune Responses; Nova Science Publishers., ISBN: 978-1-62417-328-8
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin 6 (IL-6) has a broad effect on cells of the immune system and those not of the immune system and often displays hormone-like characteristics that affect homeostatic processes. IL-6 has context-dependent pro- and anti-inflammatory properties and is now regarded as a prominent target for clinical intervention. However, the signaling cassette that controls the activity of IL-6 is complicated, and distinct intervention strategies can inhibit this pathway. Clinical experience with antagonists of IL-6 has raised new questions about how and when to block this cytokine to improve disease outcome and patient wellbeing. Here we discuss the effect of IL-6 on innate and adaptive immunity and the possible advantages of various antagonists of IL-6 and consider how the immunobiology of IL-6 may inform clinical decisions.
    Nature Immunology 04/2015; 16(5):448-457. DOI:10.1038/ni.3153 · 24.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Conventional chemotherapy and radiotherapy for the treatment of lymphoma have notable drawbacks, and passive immunotherapy using a monoclonal antibody is restricted to CD20-positive B cell lymphoma. Therefore, new treatment types are urgently required, especially for T cell lymphoma. One type of new antitumour therapy is the use of active immunotherapeutic agents, such as agonists of the Toll-like receptors (TLRs), which facilitate the induction of prolonged antitumour immune responses. Methods We have synthesised a novel TLR7 agonist called SZU-101 and investigated the systemic antitumour effect on a murine model of T cell lymphoma in vivo. Results Here, we report that the intratumoural administration of SZU-101 enhanced the effectiveness of a conventionally used chemotherapeutic agent, doxorubicin (DOX). SZU-101 administration improved tumour clearance in a murine model of T cell lymphoma. The novel combination of intratumourally administered SZU-101 and DOX generated strong cytokine production and enhanced the cytotoxic T lymphocyte response, leading to the eradication of both local and distant tumours in tumour-bearing mice. Conclusions These findings suggested that combined active immunotherapy can be developed as a promising treatment for T cell lymphoma, which may further improve the effectiveness of the current standard cyclophosphamide, DOX, vincristine and prednisone (CHOP) therapy. Electronic supplementary material The online version of this article (doi:10.1186/s13045-015-0121-9) contains supplementary material, which is available to authorized users.
    Journal of Hematology & Oncology 03/2015; 8(1). DOI:10.1186/s13045-015-0121-9 · 4.93 Impact Factor


Available from